Tempest Therapeutics (NASDAQ:TPST) Trading Up 1.1% – Time to Buy?

Shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) were up 1.1% during mid-day trading on Wednesday . The company traded as high as $2.97 and last traded at $2.87. Approximately 100,280 shares changed hands during mid-day trading, an increase of 7% from the average daily volume of 94,017 shares. The stock had previously closed at $2.84.

Wall Street Analyst Weigh In

A number of analysts recently commented on TPST shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempest Therapeutics in a research report on Monday. Wall Street Zen raised Tempest Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 11th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $12.50.

Tempest Therapeutics Stock Performance

The stock has a market cap of $14.15 million, a P/E ratio of -0.29 and a beta of -2.42. The business’s 50-day moving average price is $5.58 and its 200-day moving average price is $7.71.

Tempest Therapeutics (NASDAQ:TPST) last released its earnings results on Wednesday, November 5th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($3.27) by $2.48. As a group, equities research analysts expect that Tempest Therapeutics, Inc. will post -1.39 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tempest Therapeutics stock. Vanguard Group Inc. increased its position in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 162,560 shares of the company’s stock after acquiring an additional 27,952 shares during the quarter. Vanguard Group Inc. owned about 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent quarter. 22.52% of the stock is currently owned by institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.